Harrow Health (HROW) PT Raised to $25 at Lake Street Capital Markets

Lake Street Capital Markets analyst Brooks O'Neil raised the price target on Harrow Health (NASDAQ: HROW) to $25.00 (from $20.00) while maintaining a Buy rating.

The analyst commented: "At this point, the opportunities with VEVYE and IHEEZO are at the core of our positive view of HROW. But HROW is beginning to see green shoots for TRIESENCE too. So far, this third important branded pharmaceutical product has passed all preliminary assays for a process performance qualification (PPQ) batch. There is more work to do on TRIESENCE, but this is encouraging. The market for TRIESENCE is large and established, and it relates to many of the same doctors who will use VEVYE and IHEEZO. Seeing is believing, and we like what we see from Harrow now. We sense the new relationships with 7 large organizations of eye care doctors have the potential to be significant and think the new head of sales may focus on the many (actually larger) such organizations not currently counted among Harrow customers. Bottom line, while we did not discuss specifics or numbers, our takeaway was definitely upbeat. We continue to feel very comfortable suggesting investors smell the flowers at HROW now. We affirm our Buy rating and are increasing our PT to $25."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Apollo Hospitals (APLH:IN) PT Raised to INR8,500 at ICICI Securities
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'